GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Price-to-Operating-Cash-Flow

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-05-13), Verrica Pharmaceuticals's share price is $8.755. Verrica Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.84. Hence, Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

VRCA's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.38
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Verrica Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.31. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.84.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 11.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 11.00% per year.

During the past 8 years, Verrica Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 20.80% per year. The lowest was -138.70% per year. And the median was 5.80% per year.


Verrica Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Verrica Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Verrica Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=8.755/-0.843
=

Verrica Pharmaceuticals's Share Price of today is $8.755.
Verrica Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Verrica Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White director, officer: President and CEO C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes officer: General Counsel C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso officer: Chief Commercial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson 10 percent owner C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk officer: Chief Operating Officer 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Headlines

From GuruFocus

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-09-2023